An interventional study of IV glucocorticoid and antihistamine and IV glucocorticoid and antihistamine (standard of care) in Allergic Reaction to Contrast Media, Hypersensitivity Reaction and Computed Tomography, sponsored by Paul Peng, MD PhD MSCR. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Paul Peng, MD PhD MSCR · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 302 studies in Hypersensitivity with a site in United States — 34 open to participants now, 42 under way, 1 of them phase 3. Hypersensitivity · United States.
Among the 302 studies in Hypersensitivity with a site in United States, this one is the 22nd largest by planned enrollment of the 221 interventional ones that give a count, is one of 12 that started in 2026, is one of 69 with no phase, reaches primary completion later than 31 of the 40 other live ones, and was the 291st registered.
1,059 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →34 of the 302 studies in Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 12+
Lumicell, Inc. · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–50
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
Qifeng Zhang · Sites in United States, China
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Hypersensitivity studies recruiting now, 38 (38%) set no upper age limit and 51 (50%) stop at 75 or younger; 55 take children under 18; 37 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 63 · Phase 3 41 · Phase 4 18
First in 1996; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 540 is above the median of 73 across 693 interventional studies indexed under Hypersensitivity.
Median enrollment 60 across the 221 interventional studies, 199 across the 77 observational. Of the 243 that completed or were terminated, 104 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 302 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Paul Peng, MD PhD MSCR as lead sponsor.
Paul Peng, MD PhD MSCR has 1 study filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
12 of the studies in Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT07447869National Institute of Allergy and Infectious Diseases (NIAID)LYmph Node eXamination in Cat Allergen Immunotherapy | 2027-01-27 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT06834165ARS Pharmaceuticals, Inc.Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy | 2027-04 |
Add all 12 to your calendar (.ics) → With an account.
Among the 302 studies in Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
1-hour Premedication for Allergy Goal in Emergency: PAGE-1 is a prospective, parallel, two-arm, non-inferiority, randomized controlled trial evaluating the safety of a 1-hour (intervention) versus a 4-hour (standard regimen) intravenous (IV) premedication protocol in adult patients in the Emergency Department (ED) with a documented iodinated contrast allergy and requiring computed tomography (CT) imaging for a high-risk indication.
Allergic or hypersensitivity reactions to iodinated contrast media are rare, estimated to occur in 0.3% to 1.4% of cases, but have decreased significantly after the switch from high-osmolar to low-osmolar contrast. Most reactions are mild, and breakthrough reactions occur regardless of the timing of premedication. IV premedication is recommended, but there is no level I evidence for its basis in the ED.
This study addresses the sparse evidence that underpins the ubiquitous multi-hour premedication protocols in EDs nationwide. It specifically challenges the existing paradigm of 4-5 hours of IV premedication, which has remarkably never been prospectively validated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
IV glucocorticoid and antihistamine 1 hour before contrast
Other: IV glucocorticoid and antihistamine
IV glucocorticoid 4 hours before contrast and IV antihistamine 1 hour before contrast
Other: IV glucocorticoid and antihistamine (standard of care)
Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately plus diphenhydramine 25 mg IV 1 hour before contrast medium administration for CT imaging
Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately 4 hours before contrast medium administration, plus diphenhydramine 25 mg IV 1 hour before contrast for CT imaging
Difference in proportion of Acute Contrast Reaction
Measurement of any contrast reaction after contrast administration
Time frame: 30 minutes
Proportion of patients eligible for intervention
Ratio of those eligible to screened
Time frame: Before randomization
Proportion randomized to intervention and control
Ratio of patients randomized to intervention and control arms, and who complete the protocol as specified
Time frame: Within 30 minutes after completion of CT imaging
Adverse events after intervention
Proportion of patients who required intramuscular epinephrine, noninvasive ventilation, or intubation
Time frame: Within 30 minutes after assessment of primary outcome
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study protocol and statistical plan
Supporting information: Study protocol, Statistical analysis plan
Time frame: Available after start date and 1 year after end of study
Access criteria: Study coordinators and key personnel
Data sharing details ↗ · redcap.rutgers.edu
Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.
Of 151 non-industry interventional studies with no phase under Hypersensitivity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 43. This study's planned 27 months is above that.
Counting every sponsor, half of 175 studies reached it within 20 months; a quarter within 5 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Jun 2026 → Sep 2026, primary completion Dec 2027 → Dec 2028 and completion Jun 2028 → Jan 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.